Received Dec 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | X024540 | OT / RA |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | — | OT |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | — | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | X024540 | OT / RA |
No additional AE; expired administered doses of VARIVAX; This spontaneous report was received from an Other health professional and refers to patients of unknown age and gender. The patients' medical history was not reported. The patients' concurrent conditions were not reported. Concomitant therapies were not reported. On 20-Oct-2025, the patients were vaccinated with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), Injection (lot #X024540, expiration date: 10-Oct-2025) (dose, route of administration were not provided) for prophylaxis (Expired product administered). The vaccine was reconstituted with sterile diluent (Hollister-Stier STERILE DILUENT). No additional adverse event was reported (No adverse event). This case is invalid because unspecified number of patients and there were no patients identifiers. Follow up was received from Other health professional and referred to a 7 -year-old Male patient. The case in no longer invalid. The patient's concomitant medications included IPVSanofi and HEP A. On 20-Oct-2025, the patient was vaccinated with a first dose of Varicella Virus Vaccine Live (VARIVAX) via Subcutaneous (Anatomical Site: Right Arm).; Sender's Comments: Priority : 5 , Is case serious : No , Index user : Index date : 2025-12-09 , MNSC number : , CLIC number : , ESTAR number : , IRMS number : 2342929 , Central date : 2025-12-08 , Classification : DMC, Attachment description : Post Marketing Basic , Safety case number :
IPVSanofi; HEP A